海昇药业
(870656)
| 流通市值：2.45亿 | | | 总市值：12.26亿 |
| 流通股本：1600.01万 | | | 总股本：8000.00万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 41,910,557.19 | 215,101,819.65 | 165,979,586.54 | 126,708,771.81 |
| 营业收入 | 41,910,557.19 | 215,101,819.65 | 165,979,586.54 | 126,708,771.81 |
| 二、营业总成本 | 22,625,437.43 | 117,244,548.25 | 89,073,883.49 | 63,077,102.6 |
| 营业成本 | 20,495,127.57 | 101,816,673.82 | 78,700,287.19 | 56,698,609.84 |
| 税金及附加 | 458,097.15 | 2,144,549.35 | 1,301,191.15 | 1,043,333.91 |
| 销售费用 | 241,774.57 | 1,587,016.64 | 941,571.05 | 568,366.15 |
| 管理费用 | 1,940,161.72 | 7,395,525.79 | 5,347,475.42 | 3,483,746.97 |
| 研发费用 | 1,954,621.71 | 9,034,133.57 | 7,082,359.06 | 4,953,819.84 |
| 财务费用 | -2,464,345.29 | -4,733,350.92 | -4,299,000.38 | -3,670,774.11 |
| 其中:利息费用 | - | 4,444.44 | 4,444.44 | 4,444.44 |
| 其中:利息收入 | 2,168,256.86 | 2,884,474.4 | 2,221,725.25 | 1,635,783.66 |
| 信用减值损失(新) | -164,580.54 | -701,803.24 | -265,465.07 | -1,215,563.37 |
| 其他收益 | 275,554.31 | 1,283,451.86 | 1,005,532.61 | 418,936.25 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 19,396,093.53 | 98,438,920.02 | 77,645,770.59 | 62,835,042.09 |
| 加:营业外收入 | 4,605 | 83,231.46 | 1,923.4 | - |
| 减:营业外支出 | - | 25,500 | 200 | - |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 19,400,698.53 | 98,496,651.48 | 77,647,493.99 | 62,835,042.09 |
| 减:所得税费用 | 2,634,650.88 | 13,740,957.64 | 10,864,169.69 | 8,869,484.81 |
| 六、净利润 | 16,766,047.65 | 84,755,693.84 | 66,783,324.3 | 53,965,557.28 |
| 其中:被合并方在合并前实现利润 | - | - | - | 53,965,557.28 |
| 持续经营净利润 | 16,766,047.65 | 84,755,693.84 | 66,783,324.3 | 53,965,557.28 |
| 归属于母公司股东的净利润 | 16,766,047.65 | 84,755,693.84 | 66,783,324.3 | 53,965,557.28 |
| (一)基本每股收益 | 0.21 | 1.41 | 1.11 | 0.9 |
| (二)稀释每股收益 | 0.21 | 1.41 | 1.11 | 0.9 |
| 九、综合收益总额 | 16,766,047.65 | 84,755,693.84 | 66,783,324.3 | 53,965,557.28 |
| 归属于母公司股东的综合收益总额 | 16,766,047.65 | 84,755,693.84 | - | - |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-12-06 | 2023-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | 标准无保留意见 |